SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Jordi Remon

Jordi Remon

Institut Gustave Roussy, Villejuif

Dr. Jordi Remon is a thoracic medical oncologist at HM CIOCC Barcelona (Centro Integral Oncológico Clara Campal) in Spain, having returned in 2025 from Gustave Roussy in Villejuif, France, where he was a consultant in thoracic oncology. His work centres on non-small-cell lung cancer, with a focus on immunotherapy and targeted therapy for EGFR-mutant disease, as well as mesothelioma and thymic malignancies; he has contributed to EORTC trials including the APPLE study of osimertinib in EGFR-mutant NSCLC. He chairs the EORTC Lung Cancer Group and is a frequent speaker and discussant at major international congresses such as the World Conference on Lung Cancer.

Connect

Jordi Remon

Featured in

Nov 16 2026
RESEARCH
Immunotherapies

Lenvatinib plus pembrolizumab gave a median PFS of 22.1 months in pretreated thymic carcinoma and B3 thymoma

Read the article

J. RemonN. GirardN. Reguart
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

Read the article

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 01 2026
RESEARCH
Targeted Therapies

RAS alterations drove resistance in about one in ten oncogene-driven lung cancers progressing on targeted therapy

Read the article

B. RicciutiJ. RemonD. Planchard
Aug 27 2026
RESEARCH
Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

Read the article

J. RemonR. Ferrara
Jul 15 2026
RESEARCH
Advanced NSCLCImmunotherapies

Proton pump inhibitors and antibiotics linked to reduced durvalumab benefit in unresectable stage III NSCLC

Read the article

A. CortelliniD. PlanchardJ. NaidooJ. RemonB. Ricciuti
Jul 14 2026
RESEARCH
Advanced NSCLCSCLCADCs

ADCs across solid tumours: an ETOP/IBCSG expert group sets the research priorities

Read the article

R. StahelS. PetersG. MountziosA. PassaroN. ReguartJ. Remon
IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde
Jun 25 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters
Jordi Remon
Oct 04 2024
ILCS 2024
Immunotherapies

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

} 25 min

J. Remon